Hemispherx Biopharma Inc. (HEB)’s Financial Results Comparing With Atara Biotherapeutics Inc. (NASDAQ:ATRA)

Hemispherx Biopharma Inc. (NYSEAMERICAN:HEB) and Atara Biotherapeutics Inc. (NASDAQ:ATRA), both competing one another are Biotechnology companies. We will contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hemispherx Biopharma Inc. N/A 66.32 10.20M -0.26 0.00
Atara Biotherapeutics Inc. N/A 0.00 186.00M -4.63 0.00

Table 1 highlights Hemispherx Biopharma Inc. and Atara Biotherapeutics Inc.’s top-line revenue, earnings per share and valuation.


Table 2 shows Hemispherx Biopharma Inc. and Atara Biotherapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Hemispherx Biopharma Inc. 0.00% -118.5% -66.5%
Atara Biotherapeutics Inc. 0.00% -50.5% -45.7%

Risk and Volatility

Hemispherx Biopharma Inc. is 153.00% less volatile than S&P 500 because the stock has a beta of -0.53. Competitively, Atara Biotherapeutics Inc.’s 160.00% volatility makes it more volatile than S&P 500, because of the 2.6 beta.


The Current Ratio of Hemispherx Biopharma Inc. is 1 while its Quick Ratio stands at 1. The Current Ratio of rival Atara Biotherapeutics Inc. is 13.8 and its Quick Ratio is has 13.8. Atara Biotherapeutics Inc. is better equipped to clear short and long-term obligations than Hemispherx Biopharma Inc.

Analyst Recommendations

In next table is shown Hemispherx Biopharma Inc. and Atara Biotherapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Hemispherx Biopharma Inc. 0 0 0 0.00
Atara Biotherapeutics Inc. 0 0 1 3.00

Competitively the consensus target price of Atara Biotherapeutics Inc. is $62, which is potential 60.29% upside.

Institutional and Insider Ownership

Roughly 5% of Hemispherx Biopharma Inc. shares are owned by institutional investors while 0% of Atara Biotherapeutics Inc. are owned by institutional investors. 2.6% are Hemispherx Biopharma Inc.’s share owned by insiders. On the other hand, insiders owned about 3.3% of Atara Biotherapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Hemispherx Biopharma Inc. 9.67% -10.27% -23.04% -37.92% -38.85% -42.95%
Atara Biotherapeutics Inc. 7.56% 16.64% 8.1% 0.28% 213.65% 137.4%

For the past year Hemispherx Biopharma Inc. had bearish trend while Atara Biotherapeutics Inc. had bullish trend.


Atara Biotherapeutics Inc. beats on 5 of the 8 factors Hemispherx Biopharma Inc.

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The companyÂ’s approved products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of sexually transmitted disease infection; and Ampligen, a product approved for sale in Argentina for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; Alferon N Injection for the treatment of various categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other viruses. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. Its clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. The company is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company also has a clinical trial collaboration agreement with Merck Sharp & Dohme B.V. to evaluate ATA129 in combination with Merck anti-programmed death receptor-1 therapy and Keytruda in patients with platinum resistant or recurrent epstein-barr virus-associated nasopharyngeal carcinoma. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.